Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioAtla, Inc. (BCAB : NSDQ)

• Company Description    BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO. Number of Employees: 61

• Price / Volume Information    Yesterday's Closing Price: $0.77 Daily Weekly Monthly 20 Day Moving Average: 939,867 shares Shares Outstanding: 58.72 (millions) Market Capitalization: $45.50 (millions) Beta: 0.92 52 Week High: $2.53 52 Week Low: $0.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 112.83% 109.08% 12 Week 94.45% 76.63% Year To Date 31.07% 16.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11085 TORREYANA ROAD - SAN DIEGO,CA 92121 USA ph: 858-558-0708 fax: - investors@bioatla.com http://www.bioatla.com

• General Corporate Information    Officers Jay M. Short - Chief Executive Officer and Director Richard A. Waldron - Chief Financial Officer Scott Smith - Director Lawrence Steinman - Director Mary Ann Gray - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077B104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 58.72 Most Recent Split Date: (:1) Beta: 0.92 Market Capitalization: $45.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 29.55% vs. Previous Quarter: -6.90% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -1,177.18 03/31/25 - -373.47 12/31/24 - -238.62 ROA 06/30/25 - -137.51 03/31/25 - -116.55 12/31/24 - -103.61 Current Ratio 06/30/25 - 1.24 03/31/25 - 2.35 12/31/24 - 3.52 Quick Ratio 06/30/25 - 1.24 03/31/25 - 2.35 12/31/24 - 3.52 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -541.04 03/31/25 - -562.51 12/31/24 - -634.33 Book Value 06/30/25 - -0.29 03/31/25 - 0.01 12/31/24 - 0.25 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©